Somatostatin analogues for refractory diarrhoea in familial amyloid polyneuropathy.

This study suggests that somatostatin analogues may benefit to patients with FAP and refractory diarrhoea. Approximately 20% of patients had severe adverse events, including hypoglycaemia.